{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:00:48Z","timestamp":1778169648149,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jtcvs.2020.11.160","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T11:09:00Z","timestamp":1607857740000},"page":"e313-e328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intrapleural interleukin-2\u2013expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Chigozirim N.","family":"Ekeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira L.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranav","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong Sheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Soloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Dhupar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtcvs.2020.11.160_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1378\/chest.117.1.73","article-title":"Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease","volume":"117","author":"Burrows","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib3","doi-asserted-by":"crossref","first-page":"e1554969","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making\u00a0cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib7","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib8","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib9","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002620050407","article-title":"Intrapleural instillation of interferon \u03b3 in patients with malignant pleurisy due to lung cancer","volume":"45","author":"Yanagawa","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2004.09.164","article-title":"Prospective randomized trial of intrapleural bleomycin versus interferon Alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions","volume":"22","author":"Sartori","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0169-5002(00)00192-6","article-title":"Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients","volume":"31","author":"Castagneto","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12885-018-4581-5","article-title":"Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients","volume":"18","author":"Han","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib16","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib17","article-title":"Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy","author":"Feist","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12967-015-0662-2","article-title":"A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells","volume":"13","author":"Acencio","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib19","first-page":"317","article-title":"Establishment of a malignant pleural effusion mouse model with Lewis lung carcinoma cell lines expressing enhanced green fluorescent protein","volume":"15","author":"Ma","year":"2012","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib20","first-page":"600","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1073\/pnas.0913939107","article-title":"High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib22","doi-asserted-by":"crossref","first-page":"e09083","DOI":"10.7554\/eLife.09083","article-title":"Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires","volume":"4","author":"Yang","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-1-4939-9773-2_17","article-title":"The adaptome as biomarker for assessing cancer immunity and immunotherapy","volume":"2055","author":"Han","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nbt.3979","article-title":"Antigen receptor repertoire profiling from RNA-seq data","volume":"35","author":"Bolotin","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nmeth.2960","article-title":"Towards error-free profiling of immune repertoires","volume":"11","author":"Shugay","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41467-019-14273-0","article-title":"Comprehensive T cell repertoire characterization of non-small cell lung cancer","volume":"11","author":"Reuben","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib28","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/0008-5472.CAN-16-2165","article-title":"Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy","volume":"77","author":"Fend","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/0008-5472.CAN-11-2788","article-title":"Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer","volume":"72","author":"John","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib30","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41598-018-19548-y","article-title":"Increased diversity with reduced \"diversity evenness\" of tumor infiltrating T-cells for the successful cancer immunotherapy","volume":"8","author":"Hosoi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib31","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.3389\/fimmu.2018.03185","article-title":"TCR repertoire analysis reveals mobilization of novel CD8(+) T cell clones into the cancer-immunity cycle following anti-CD4 antibody administration","volume":"9","author":"Aoki","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib32","doi-asserted-by":"crossref","first-page":"OF5","DOI":"10.1158\/2159-8290.CD-NB2020-040","article-title":"Tumor-infiltrating lymphocytes help rein in NSCLC","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-009-0602-z","article-title":"Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model","volume":"122","author":"Iankov","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib34","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1200\/jco.2015.33.15_suppl.7559","article-title":"Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion","volume":"33","author":"Krug","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-030-38862-1_4","article-title":"Adaptive immunity and the tumor microenvironment","volume":"180","author":"Lotze","year":"2020","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","article-title":"CR repertoire diversity of peripheral PD-1(+)CD8(+) T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer","volume":"8","author":"Han","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib37","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00432-019-03070-3","article-title":"First-line PD-1\/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or\u00a0<\u00a01% PD-L1-expressing metastatic non-small-cell lung cancers","volume":"146","author":"Landre","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib39","doi-asserted-by":"crossref","first-page":"102980","DOI":"10.1016\/j.critrevonc.2020.102980","article-title":"Double immune checkpoint blockade in advanced NSCLC","volume":"152","author":"Mariniello","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib40","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/mt.2011.228","article-title":"Treating tumors with a vaccinia virus expressing IFN\u03b2 illustrates the complex relationships between oncolytic ability and immunogenicity","volume":"20","author":"Wang","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s40425-019-0785-8","article-title":"Tumor\u00a0microenvironment dictates regulatory T cell phenotype: upregulated immune checkpoints reinforce suppressive function","volume":"7","author":"Kim","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtcvs.2020.11.160_bib42","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522320333377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522320333377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T17:17:15Z","timestamp":1758388635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522320333377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0022522320333377"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2020.11.160","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrapleural interleukin-2\u2013expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2020.11.160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.","name":"copyright","label":"Copyright"}]}}